Treatment for diffuse benign breast diseases
- 作者: Kravchenko E.N.1, Naboka M.V.1
-
隶属关系:
- Omsk State Medical University, Ministry of Health of Russia
- 期: 编号 2 (2023)
- 页面: 140-145
- 栏目: Exchange of Experience
- URL: https://journals.rcsi.science/0300-9092/article/view/258675
- DOI: https://doi.org/10.18565/aig.2023.25
- ID: 258675
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Timely treatment for benign breast dysplasia (BBD) should be considered as a cancer prevention measure.
Objective: To evaluate the efficiency of BBD treatment with the non-hormonal herbal remedy indole carbinol (Indinol Forto).
Materials and methods: A total of 150 women aged 30–49 years were comprehensively examined using breast examination and sonography and mammography. The patients were divided into 2 groups. A study group consisted of 75 women with BBD: with benign changes (according to Breast Imaging-Reporting and Data System 2 (BI-RADS 2), manifested as small cysts (up to 10 mm), as well as duct ectasias concurrent with cyclical mastalgias. All the patients were prescribed combination treatment, including concomitant measures. The study group women took indole carbinol-based drugs to treat BBD. A comparison group included 75 women with benign changes (BI-RADS 2), who refused drug treatment for various reasons.
Results: Minor mammographic density was noted in 69.3% of the study group patients and in 34.7% of the comparison group (p<0.001); moderate one was seen in 26.6 and 42.7%, respectively (p=0.040). Severe mammographic density was determined in 2.7% of cases in the study group and in 13.3% of those in the comparison group (p=0.017); pronounced one was observed in 1.3% and 9.3% in these groups, respectively (p=0.030).
Conclusion: Indinol Forto is shown to be highly effective in treating BBD. Combined with concomitant measures, 6-month therapy with this drug substantially reduces mammographic density. The drug is well tolerated and has no adverse side effects. It can be recommended for widespread use as a first-line drug in women with increased breast density.
作者简介
Elena Kravchenko
Omsk State Medical University, Ministry of Health of Russia
编辑信件的主要联系方式.
Email: kravchenko.en@mail.ru
Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology No. 1
俄罗斯联邦, OmskMaxim Naboka
Omsk State Medical University, Ministry of Health of Russia
Email: nabokamax@mail.ru
Assistant, Department of Oncology, Radiation Therapy
俄罗斯联邦, Omsk参考
- Kaprin A.D., Rozhkova N.I., eds. Mammology: a national guide. Moscow: GEOTAR-Media; 2016. (in Russian).
- Rozhkova N.I., Burdina I.I., Zapirova S.B., Mazo M.L., Prokopenko S.P., Yakobs O.E. Early treatment of diffuse hyperplasia – is a prevention of breast cancer. Oncogynecology. 2016; (1): 4-11. (in Russian).
- Ruzhenkov V.A., Shulichenko E.A. Mental dysfunction among women with symptomatic benign dys-plasia of the breast. Modern Problems of Science and Education. 2016; (4): 52. (in Russian).
- Kerchelaeva S.B., Smetnik A.A., Bespalov V.G. Mastopathy and breast cancer prevention as interdisciplinary problem. RMJ. 2016; 24(15): 1018-25. (in Russian).
- Kravchenko E.N., Ozhereleva M.A. State of breast to the gynecological disease. Mother and Child in Kuzbass. 2014; (2): 19-23. (in Russian).
- Suturina L.V. Modern approaches to risk assessment and prevention of breast diseases. Women's Health and Reproduction. 2019; 9-10: 3-15. (in Russian).
- Kiselev V.I., Smetnik V.P., Suturina L.V., Selivanov S.P., Rudakova E.B., Rakhmatullina I.R., Andreyeva E.N., Fadeyeva N.I., Khasanov R.Sh., Kulagina N.V., Rozhkova N.I., Artymuk N.V., Gavisova A.A., Muizhnek E.L., Kuznetsov I.N., Drukh V.M. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology. 2013; (7): 56-63. (in Russian).
- Smetnik V.P., Gavisova A.A., Bilak N.P., Drukh V.M. Indolecarbinol efficacy for mastalgia treatment. Russian Journal of Human Reproduction. 2013; (5): 4953. (in Russian).
- Levakov S.A., Kaviladze M.G., Gelashvili A.Z. The effectiveness of the drug Indinol forto in patients with dyshormonal diseases of the mammary glands. Pharmacology & Pharmacotherapy. 2022; (1): 90-4. (in Russian). https://dx.doi.org/10.46393/27132129_2022_1_90.
- Khiyaeva V.A. Experience with indolecarbinol used to treat mastopathy. Medical Council. 2019; (13): 154-8. (in Russian). https://dx.doi.org/10.21518/2079-701X-2019-13-154-158.
- Tazina T.V. Pathogenetically based therapy for cyclic mastalgia. Obstetrics and Gynecology. 2020; (9): 187-90. (in Russian). https://dx.doi.org/10.18565/ aig.2020.9.187-190.
- Tazina T.V. A modern approach to therapy for cyclic mastalgia in comorbid patients. Obstetrics and Gynecology. 2021; (5): 158-64. (in Russian). https://dx.doi.org/10.18565/aig.2021.5.158-164.
- Borovikov I.O., Kutsenko I.I., Bulgakova V.P., Borovikova O.I. Non-hormonal therapy of patients with fibrocystic mastopathy in combination with endometrial hyperplasia. Medical Council. 2021; (21-1): 182-9. (in Russian). https://dx.doi.org/10.21518/ 2079-701X-2021-21-1-182-189.
补充文件
